In-Vitro Inhibitory Efficacy of 3 Types of Probiotics on the Growth of Aggregatibacter actinomycetemcomitans Bacteria
Frontiers in Bioscience-Landmark · 2023
DOI: 10.31083/j.fbl2805106 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Bioscience-Landmark, 2023. Verfasst von Chiquita P Sulistiowati und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Periodontology, Universitas Airlangga, 160132 Ulfah, Indonesia. Hauptthemen laut MEDLINE: Lacticaseibacillus casei, Probiotics. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Universitas Airlangga.
Abstract (Originalsprache)
Background
Amongst the specific plaque pathogen Aggregatibacter actinomycetemcomitans (Aa) ATCC 43718 serotype b is one of the highly virulent bacteria that causes periodontitis. Probiotic therapy is a treatment in which the lactic acid bacteria in are utilized to impede the colonization and growth of the pathogenic bacteria to prevent the further formation of dental plaque.
Objective
The present research aimed to evaluate inhibiting effect of purified bacteria from various commercially available yogurt product containing bacteria named (Lactobacillus casei strain Shirota; Lactobacillus bulgaricus and Streptococcus thermophilus; Lactobacillus reuteri Prodentis) on the growth of Aa.
Methods
The research made use of the diffusion method by fixing Aa on BHIB (brain heart infusion broth) medium, incubated at 37 °C and 24 hours later planted on MHA (Mueller-Hinton agar) media. Aa were divided into four subgroups each with a paper disk; group 1 consists of untreated bacteria (i.e., control group), group 2 with purified bacteria from Yakult 0.5 μL, group 3 with purified bacteria from Cimory Yogurt Drink 0.5 μL and group 4 with purified bacteria from BioGaia Prodentis 0.5 μL. All commercially available yogurt were treated to get the purified probiotic. Additionally, it was incubated for 24 hours at 37 °C and later the inhibition zone diameter was observed.
Results
In the research, it was found that the average impeding ability, so-called inhibition zone, in group 1 indicated 0 mm, group 2 indicated 12.70 mm, group 3 indicated 16.60 mm and group 4 indicated 19.60 mm. The statistical test outcomes showed a significance of 0.000 (p < 0.05).
Conclusions
The purified bacteria from three probiotics indeed inhibit the growth of the Aa bacteria and a substantial difference in the diameter of the inhibition zone were found among the three probiotics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Periodontology, Universitas Airlangga, 160132 Ulfah, Indonesia.
- Department of Periodontics and Community Dental Sciences, College of Dentistry, King Khalid University, 62529 Abha, Saudi Arabia.
- Department of Periodontics, Datta Meghe Institute of Higher Education and Research, Deemed to be University, 442001 Wardha, India.
Förderung
- Universitas Airlangga
Zitieren
APA
Sulistiowati, C. P., Suhartono, M., Rahmawati, D. F., Ulfah, N., Supandi, S. K., Wijaksana, I. K. E., Abullais, S. S., & Dhadse, P. (2023). In-Vitro Inhibitory Efficacy of 3 Types of Probiotics on the Growth of Aggregatibacter actinomycetemcomitans Bacteria. Frontiers in Bioscience-Landmark. https://doi.org/10.31083/j.fbl2805106
Vancouver
Sulistiowati CP, Suhartono M, Rahmawati DF, Ulfah N, Supandi SK, Wijaksana IKE, et al. In-Vitro Inhibitory Efficacy of 3 Types of Probiotics on the Growth of Aggregatibacter actinomycetemcomitans Bacteria. Frontiers in Bioscience-Landmark. 2023. doi:10.31083/j.fbl2805106
BibTeX
@article{Sulistiowati2023,
author = {Sulistiowati, Chiquita P and Suhartono, Michelle and Rahmawati, Diana F and Ulfah, Noer and Supandi, Shafira K and Wijaksana, I Komang Evan and Abullais, Shahabe Saquib and Dhadse, Prasad},
title = {In-Vitro Inhibitory Efficacy of 3 Types of Probiotics on the Growth of Aggregatibacter actinomycetemcomitans Bacteria},
journal = {Frontiers in Bioscience-Landmark},
year = {2023},
doi = {10.31083/j.fbl2805106}
}
EUVIMED